OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting [Yahoo! Finance]
OKYO Pharma Limited - Ordinary Shares (OKYO)
Company Research
Source: Yahoo! Finance
investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announces that an abstract on its lead candidate, urcosimod (formerly OK-101), has been accepted for presentation at the prestigious 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. The accepted paper, titled "Evaluation of Urcosimod in Neuropathic Corneal Pain: Efficacy and Safety Results from a Proof-of-Concept Pilot Phase 2 Study" , will be presented in the Ocular Surface Disease II session on Saturday, April 11, 2026, from 3:30 PM to 5:00 PM at the meeting in Washington, DC. This acceptance follows a rigorous and highly competitive review process by the ASCRS Annual Meeting Program Committee, where only a limited number of submissions are selected each year. The abstract highlights efficacy and safety data from OKYO's recently completed proof-of-concept Phase 2 study of urcosimod in patients with neuropathic corneal pain. Robe
Show less
Read more
Impact Snapshot
Event Time:
OKYO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OKYO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OKYO alerts
High impacting OKYO Pharma Limited - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
OKYO
News
- OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual MeetingGlobeNewswire
- OKYO Pharma (NASDAQ:OKYO) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- OKYO Pharma Announces Successful Type C Meeting with the FDAGlobeNewswire
- FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal PainGlobeNewswire
- OKYO Pharma Limited's (NASDAQ:OKYO) Intrinsic Value Is Potentially 90% Above Its Share Price [Yahoo! Finance]Yahoo! Finance
OKYO
Sec Filings
- 2/2/26 - Form F-3
- 1/30/26 - Form 6-K
- 1/30/26 - Form 6-K
- OKYO's page on the SEC website